Skip to content

A systematic review on mindfulness-based immersive interventions in depressive disorders

Peng Tan, Yuqi Wu, Xinrong Chen, Jie Chen, Zhixing Guo, Xiaobing Lu, Hongtao Zhang

npj Mental Health Research April 2, 2026 DOI: 10.1038/s44184-026-00205-6 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review Peer reviewed
Sample size 37
Topics Anxiety Depression Meditation
Keywords Psychological intervention Rumination Neurocognitive Cognition Systematic review Depressive symptoms Clinical trial Medline Clinical psychology Psychotherapist Affect linguistics Disease
Citations 3
Key findings Mindfulness-based immersive interventions (MBIIs) were associated with greater improvements in depressive and anxiety symptoms compared with conventional therapies in 69% of included studies.

Abstract

Depressive disorders are characterized by persistent negative affect, rumination, and impaired emotion regulation, contributing substantially to global disease burden. As recurrent rumination and negative attentional biases are central cognitive mechanisms of depression, interventions targeting these processes have gained increasing attention. Mindfulness-based interventions (MBIs) effectively treat depressive disorders but face adherence challenges, which immersive technology may resolve through multi-sensory stimulation and real-time feedback. This systematic review assesses the therapeutic potential of mindfulness-based immersive interventions (MBIIs, which combine immersive technologies with MBIs) for depressive disorders. Following PRISMA guidelines, we identified 37 eligible studies from 670 screened records. Across the included studies, a proportion of studies (69%) reported greater improvements in depressive and anxiety-related symptoms in MBII conditions compared with conventional therapies, while 78% of the trials reported improvements in psychological processes. A subset of trials reported greater feasibility and acceptance for immersive implementations compared with non-immersive approaches (67%), and 89% reported improvements in physiological outcomes. However, significant gaps remain, including substantial variability in sessions and VR configurations, insufficient active controls, and limited long-term validation. Future research is recommended to prioritize mechanistic studies to clarify neurocognitive pathways, standardize sessions, and evaluate cost-effectiveness.

Comparable studies

Other systematic reviews and meta-analyses on depression, most cited first.

Study Year Design Participants
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression Participants with major depression in placebo-controlled, double-blind, randomized... 2015 Systematic review and meta-analysis
Side-effects associated with ketamine use in depression: a systematic review. Patients with depression 2018 Systematic review
Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Adults with unipolar or bipolar major depression 2020 Systematic review and meta-analysis n = 1,877
Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Patients with major depressive disorder or bipolar depression 2016 Systematic review and meta-analysis n = 588
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Patients with cancer- or illness-related anxiety and depression, major depressive... 2020 Systematic review n = 188

Citations in the library

Explore topics